Traditional Chinese medicine composition for treating lung cancer and application thereof

Through a composition composed of multiple Chinese medicines, the treatment of lung cancer has solved the problem of unknown mechanism of action and insufficient bioavailability of Chinese medicine compound prescriptions, and the effective inhibition and immune regulation of lung cancer is achieved. It is suitable for different types and stages of Patients have significantly improved the treatment effect and quality of life, and promoted the development of the traditional Chinese medicine industry.

CN118903322AActive Publication Date: 2024-11-08SHANGHAI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410942067.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-08
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

When treating lung cancer, the existing Chinese medicine compound prescriptions have unclear mechanisms of action, complex composition, insufficient bioavailability and efficacy stability, insufficient clinical safety and effectiveness assessment, and lack of evidence to effectively prevent and treat metastasis and prolong survival time.

Method used

Using a traditional Chinese medicine composition composed of raw Astragalus, Argan Salvia ginseng, Asparagus, Ophiopogon japonicus, Poria cocos, Shishang cypress, Shijian Chuan, Chonglou, Shanci mushroom, Sugar thorn, Houttuynia cordata, and Ligustrum, and boiled by decoction. Or process it into different dosage forms, combined with traditional Chinese medicine theory to optimize the compatibility, inhibit the proliferation and metastasis of lung cancer cells and regulate immune function.

Benefits of technology

It significantly improves the treatment effect of lung cancer, has few side effects, and is suitable for patients with lung cancer of different types and stages, enhancing immunity, improving quality of life, reducing medical burden, and promoting the industrialization of traditional Chinese medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903322A_ABST
    Figure CN118903322A_ABST
Patent Text Reader

Abstract

The invention discloses a traditional Chinese medicine composition for treating lung cancer, which is prepared from the following raw material medicines in parts by weight: 15-30 parts of raw radix astragali, 10-15 parts of radix glehniae, 10-15 parts of radix asparagi, 10-15 parts of radix ophiopogonis, 10-15 parts of poria cocos, 15-30 parts of selaginella doederleinii hieron, 15-30 parts of salvia chinensis, 15-30 parts of paris polyphylla, 15-30 parts of edible tulip, 15-30 parts of selfheal, 15-30 parts of houttuynia cordata and 10-15 parts of glossy privet fruit. The traditional Chinese medicine composition can inhibit proliferation of lung cancer cells, promote apoptosis of the lung cancer cells, exert the effect of resisting invasion and metastasis of the lung cancer by intervening in exosomes, improve clinical symptoms of tumor patients, regulate functional immunity and improve life quality.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a traditional Chinese medicine composition for treating lung cancer and use thereof. The traditional Chinese medicine composition is applied to the treatment of malignant tumors in clinic, mainly targeting lung malignant tumors, especially metastasis. Background Art

[0002] The present invention mainly discovers and verifies a group of Chinese medicine compositions, which can be used to treat lung cancer, including the occurrence and metastasis of lung cancer. The main features of the prior art related to the present invention are as follows: 1. Compound medicine: Under the combination of traditional Chinese medicine theory and modern pharmacology, a Chinese medicine prescription for treating lung cancer is formed, but its mechanism is difficult to explain due to the complex ingredients; 2. Chinese medicine monomer: Taking the monomer of a certain Chinese medicine as the research object, its anti-tumor effect and mechanism are explained, but the "theoretical" essence of Chinese medicine is lost; 3. Regulating immunity: Immune function is one of the most important components of Chinese medicine's positive energy, and the essence of the role of "strengthening" of Chinese medicine is revealed from the perspective of regulating immunity; 4. Increasing efficacy and reducing toxicity: From the perspective of enhancing the efficacy of modern medicine in clinical practice and reducing adverse reactions in the process of modern medical treatment, find evidence-based medical evidence of the effectiveness of Chinese medicine; 5. Quality of life: The existing Chinese medicine compositions mainly improve the quality of life and relieve clinical symptoms as the main function, lacking evidence-based medical evidence and mechanism of action research for preventing and treating metastasis and prolonging survival time.

[0003] The deficiencies of the technology most relevant to the invention are mainly manifested as follows: first, the main mechanism of action, active ingredients and efficacious ingredients of the Chinese medicine compound still need to be studied in depth; second, the Chinese medicine compound has a complex composition and a variety of medicinal flavors, resulting in an unclear mechanism of action. How to optimize the Chinese medicine compound to form a "simple, convenient, cheap and effective" prescription; third, the preparation process of the Chinese medicine composition needs to be improved urgently, especially to improve its bioavailability and efficacy stability; finally, the clinical safety evaluation and effectiveness evaluation of the Chinese medicine composition also need to be more scientific and rigorous, and more detailed evaluation indicators and systems should be formulated. Summary of the invention

[0004] In view of the above-mentioned deficiencies in the prior art, according to an embodiment of the present invention, it is hoped to provide and verify a Chinese medicine composition for treating lung cancer, which is mainly used for the treatment of lung cancer, including the occurrence and metastasis of lung cancer.

[0005] According to the embodiment, the present invention provides a Chinese medicine composition for treating lung cancer, which is prepared by the following raw medicines in parts by weight: 15-30 parts of raw astragalus, 10-15 parts of northern adenophora, 10-15 parts of asparagus, 10-15 parts of ophiopogon, 10-15 parts of tuckahoe, 10-15 parts of stone cypress, 15-30 parts of stone stalk, 15-30 parts of paris paris, 15-30 parts of trifoliate vine, 15-30 parts of selfheal, 15-30 parts of houttuynia, and 10-15 parts of glossy privet. Preferably, the weight parts of the raw medicines are: 30 parts of raw astragalus, 15 parts of northern adenophora, 15 parts of asparagus, 15 parts of ophiopogon, 15 parts of tuckahoe, 15 parts of tuckahoe, 15 parts of stone cypress, 15 parts of stone stalk, 30 parts of paris paris, 15 parts of trifoliate vine, 15 parts of selfheal, 15 parts of houttuynia, and 15 parts of glossy privet.

[0006] The following examples and test cases of the present invention will demonstrate the effective ingredients of the Chinese medicine composition that enter the blood and lung tissue, the network pharmacology analysis of the Chinese medicine composition and the associated targets of the Chinese medicine composition-disease, the cytological and animal experiments of the Chinese medicine composition in preventing and treating the occurrence and metastasis of lung cancer, and the mechanism of action of the Chinese medicine composition in preventing and treating the occurrence and metastasis of lung cancer may be related to the inhibition of exosome protein expression. That is, the Chinese medicine composition of the present invention can inhibit the proliferation of lung cancer cells and promote their apoptosis, and at the same time, through the intervention of exosomes, it can play an anti-lung cancer invasion and metastasis effect, improve the clinical symptoms of tumor patients, regulate functional immune function, and improve the quality of life.

[0007] The preparation method of the Chinese medicine composition of the present invention is not special. The raw material components that meet the requirements of the national "Pharmacopoeia" and other regulations are uniformly mixed according to the weight ratio of claim 2; decocted into a decoction, or processed into clinical granules, pills (water pills or drop pills), Chinese medicine formula granules, or added with one or more excipients acceptable in the pharmaceutical preparation process, and made into granules, water pills, tablets or capsules according to conventional processes.

[0008] The advantages of the Chinese medicine composition for treating lung cancer of the present invention are mainly as follows: 1. Significant curative effect: The Chinese medicine composition selects Chinese medicinal materials with the effects of softening and dispersing nodules, clearing away heat and detoxifying, invigorating qi and nourishing yin, strengthening the spleen and tonifying the kidney according to the theory of traditional Chinese medicine, and achieves the inhibition of cancer cells and improves the therapeutic effect through the scientific compatibility of drugs and dosages; 2. Small side effects: Compared with some chemical drugs, the side effects of the Chinese medicine composition are usually small, and the impact on the quality of life of patients is relatively low, and the components of the Chinese medicine composition of the present invention are clear and safe; 3. Overall regulation: The Chinese medicine composition of the present invention emphasizes the overall concept, starting from the three internal organs of the lung, spleen and kidney, the composition not only pays attention to inhibiting the tumor itself, but also pays attention to regulating the patient's overall condition, including enhancing immunity, improving physical fitness, etc., so as to help patients better cope with the disease; 4. Wide applicability: The Chinese medicine composition of the present invention is guided by the theory of traditional Chinese medicine, and is personalized in dosage and medicinal flavor according to the clinical characteristics of lung cancer, so it can be applicable to patients with lung cancer of different types and stages, especially patients after lung cancer surgery.

[0009] The social and economic value of the Chinese medicine composition for treating lung cancer of the present invention is mainly reflected in the following aspects: 1. Reducing the medical burden: Since the Chinese medicine composition is usually relatively low in price and has little side effects, it can reduce the medical burden of patients to a certain extent, so that more patients can enjoy effective treatment; 2. Promoting the industrialization of traditional Chinese medicine: As people's recognition of the efficacy of traditional Chinese medicine continues to increase, the development of the traditional Chinese medicine industry will also be further promoted. This will help to enhance the competitiveness of traditional Chinese medicine in the international market and promote the international development of the traditional Chinese medicine industry; 3. Improving social benefits: By promoting and applying effective traditional Chinese medicine compositions to treat lung cancer, the survival rate and quality of life of lung cancer patients can be improved, and the social burden caused by the disease can be reduced, thereby improving social benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 The main components and metabolites of the Chinese medicine composition of the present invention (hereinafter also referred to as Feiyanshu) in peripheral blood and lung tissue and 8 prototype components are shown.

[0011] Figure 2 It shows that Feiyanshu has a total of 182 related target intersections between drugs and lung cancer metastasis.

[0012] Figure 3 PPI network analysis showing intersectional targets, with TLR4 at position 20.

[0013] Figure 4 Showing LungYanShu-Disease Target.

[0014] Figure 5 KEGG pathway analysis showing the effect of Feiyanshu on tumor treatment.

[0015] Figure 6The David database is used to analyze the lung Yanshu-disease targets and the KEGG signaling pathway for fitting analysis.

[0016] Figure 7 GO analysis of Feiyanshu-disease targets was performed.

[0017] Figure 8 The drug-target analysis network of Feiyanshu is shown.

[0018] Fig. 9 The results showed that Feiyanshu has a preventive and therapeutic effect on lung metastasis in mice with tail vein lung metastasis model.

[0019] Fig.10 It showed that Feiyanshu could inhibit the expression of exosome proteins in the lung tissue of tumor-bearing mice.

[0020] Fig.11 Studies showing the cytotoxic effects of Feiyanshu on CTC-TJH-01 and H1299 cells.

[0021] Fig.12 The study shows the effect of different concentrations of Feiyanshu on the invasion and migration of CTC-TJH-01 and H1299 cells.

[0022] Fig.13 Shows the PKH26-labeled exosomes and tumor cells co-culture tracking experiment.

[0023] Fig.14 Showing the effect of Feiyanshu on the expression of exosome proteins in the culture supernatant of CTC-TJH-01 and H1299 cells. DETAILED DESCRIPTION

[0024] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments. These embodiments should be understood to be only used to illustrate the present invention and not to limit the scope of protection of the present invention. After reading the contents of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent changes and modifications also fall within the scope defined by the claims of the present invention.

[0025] Example 1

[0026] Weigh 30g of raw Astragalus, 15g of Glehnia littoralis, 15g of Asparagus cochinchinensis, 15g of Radix Ophiopogonis, 15g of Poria, 15g of Platycodon grandiflorum, 15g of Ipomoea aquatica, 30g of Paris polyphylla, 15g of Tripterygium wilfordii, 15g of Herba Prunellae, 15g of Herba Houttuyniae, and 15g of Fructus Ligustri Lucidi that meet the requirements of the Pharmacopoeia. Decoction into decoction, or process into clinical granules, pills, Chinese medicine granules, or add one or more excipients acceptable in the pharmaceutical preparation process, and prepare into granules, water pills, freeze-dried powder, tablets or capsules according to conventional processes.

[0027] Test example

[0028] 1. The metabolites and distribution patterns of Feiyanshu in the peripheral blood and lung tissue of mice.

[0029] 1.1 Instruments and reagents

[0030] Waters H-Class ultra-high performance liquid chromatograph (Waters Technology Co., Ltd.); AB Sciex Triple 4600 high-resolution mass spectrometer (SCIEX); KQ-300BD ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.); SIGMA 3K15 high-speed centrifuge (SIGMA); LNG-T98 centrifugal concentration dryer (Taicang Huamei Biochemical Instrument Factory); methanol and acetonitrile, mass spectrometry grade, purchased from Merck; formic acid, mass spectrometry grade, purchased from Shanghai Anpu Experiment Technology Co., Ltd.

[0031] 1.2 Experimental animals

[0032] Twenty-four healthy male C57 mice, weighing 20-22 g and 8 weeks old; provided by Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd., certificate number SCXK(Su)2020-0009; raised in Shanghai Xinying Biotechnology Co., Ltd., with an indoor temperature of 22-26°C, a relative humidity of 40%-70%, and a light / dark time of 12 h each.

[0033] 1.3 Experimental methods

[0034] A. Feiyanshu Test sample: lyophilized powder (150.39 g) prepared in Example 1, stored at 4°C for later use.

[0035] B. Weigh about 1.0 g of the test sample accurately, place it in a 50 ml stoppered conical flask, add 10 ml of 50% methanol, treat it with ultrasound (power 300 W, frequency 40 kHz) for 30 minutes, take 2 ml into a centrifuge tube, centrifuge at high speed (12000 rpm) for 5 minutes, and take the supernatant.

[0036] 1.4 Chromatographic and mass spectrometry conditions

[0037] A. Chromatographic conditions: Waters ACQUITY UPLC HSS T3 column (2.1×150mm, 1.8μm); mobile phase A is acetonitrile, and phase B is 0.1% formic acid aqueous solution. Elution program is 0-4min, 0% acetonitrile; 4-8min, 0%-8% acetonitrile; 8-28min, 8%-20% acetonitrile; 28-46min, 20%-35% acetonitrile; 46-51min, 35%-60% acetonitrile; 51-54min, 60%-90% acetonitrile; 54-57min, 90% acetonitrile; 57-57.1min, 90%-0% acetonitrile; 57.1-60min, 0% acetonitrile. Column temperature was 30℃; flow rate was 0.3ml / min; injection volume for detecting compound components was 2μl, injection volume for detecting blood and tissue components was 5μl; detection wavelengths were 254nm, 190~400nm.

[0038] B. Mass spectrometry conditions: mass spectrometry detection mode is ESI-Negative / Positive ion mode; mass range is 50-1700; secondary mass range is 50-1250; spray gas pressure is 50 (psi); declustering voltage is 100 (V); auxiliary heating gas pressure is 50 (psi); collision voltage is ±40 (eV); curtain gas pressure is 35 (psi); collision voltage swing is 20 (eV); ionization voltage is -4500 / 5000 (V); ion release delay is 30 (ms); ion source temperature is 500 (℃); ion beam width is 15 (ms); declustering voltage is 100 (V); collision voltage is 10 (eV).

[0039] C. Serum and tissue sample collection: Mice were randomly divided into 4 groups (blank, 1h group, 2h group and 4h group, 6 mice in each group). Ultrapure water was given to the blank group and 130 g·kg was given to the drug group using a 12G gavage needle. -1 The animals were gavaged with an aqueous solution of Feiyanshu lyophilized powder (the dose was calculated as twice the equivalent dose for a 70 kg adult) for 3 consecutive days. At the end of the third day, blood was collected from the eye sockets into a non-anticoagulated 1.5 ml EP tube and centrifuged at 8000×g for 5 min to obtain serum. Lung tissue was dissected and residual blood on the surface was washed with 0.9% saline and dried with filter paper. All samples were stored at -80°C for later use.

[0040] D. Serum sample processing: Blank serum (1.5 ml) and administration serum (3.5 ml) were combined, and 3 times the amount of methanol (mass spectrometry grade) was added to precipitate protein, vortexed for 5 minutes, allowed to stand for 20 minutes (4°C), centrifuged for 15 minutes (12000 rpm), and the supernatant was collected, centrifuged and concentrated to dryness, and stored at -80°C. Before analysis, the residue was re-dissolved in 80 μl of 50% methanol, vortexed for 3 minutes, centrifuged for 15 minutes (12000 rpm), and the supernatant was collected.

[0041] E. Lung tissue sample processing: Weigh the lung tissue before administration (1g) and the lung tissue after administration (3g), accurately weigh them, place them in several 2ml centrifuge tubes, add 1.5ml ice methanol and grind for 30s, ultrasonicate in an ice bath (power 300W, frequency 40KHz) for 15 minutes, centrifuge for 15 minutes (12000rpm), combine the supernatant, centrifuge and concentrate to dryness, and store at -80℃. Before analysis, add 200μl methanol to re-dissolve the residue, vortex mix for 3 minutes, centrifuge for 15 minutes (12000rpm), and take the supernatant.

[0042] 1.5 Analysis software

[0043] The data acquisition software was Analyst TF 1.7.1, and the data processing software was Peakview 1.2.

[0044] 1.6 Results

[0045] Ultra performance liquid chromatography-high resolution mass spectrometry (UPLC-Q-TOF / MS) was used to analyze serum and lung tissue samples of Feiyanshu. According to the multi-level mass spectrometry information of the samples, relevant literature and the identification results of the original formula, 56 components were identified from serum samples of Feiyanshu, including 9 prototype components and 47 metabolites; 40 components were identified from lung tissue samples of Feiyanshu, including 8 prototype components and 32 metabolites. Among them, the 8 prototype components expressed in both serum and lung tissue were as follows Figure 1 As shown, it is mainly derived from raw astragalus, cypress and Ligustrum lucidum.

[0046] 2. Network pharmacology and target analysis of Feiyanshu.

[0047] 2.1 The drug components of Radix Astragali, Radix Glehniae, Radix Asparagi, Radix Ophiopogonis, Poria, Radix Platycodonis, Radix Ilex, Rhizoma Paridis, Rhizoma Paridis, Rhizoma Paridis, Herba Cibotii, Herba Prunellae, Herba Houttuyniae, and Fructus Ligustri Lucidi were found and screened in Symmap and Swiss ADME databases. The drug targets were predicted by SwisstargetPrediction and then the intersection with the Pulmonary metastases targets retrieved from Genecard and OMIM databases was obtained to obtain 182 related targets, such as Figure 2 shown.

[0048] 2.2 182 related targets were sorted in the Cytoscape database, and the first half of the degree values, i.e. the first 91 targets, were taken to construct the PPI network diagram, as shown in Figure 3 As shown, Tp53 was found to be the primary target, and TLR4 was the 20th target.

[0049] 2.3 Organize the Metascape database lung rock-shu-disease targets in the Cytoscape database, such as Figure 4 As shown, a potential target interaction network was formed.

[0050] 2.4 KEGG analysis was performed on 91 targets, such as Figure 5 As shown in the results, it was found that Feiyanshu can treat tumors and may play a role through the NF-KappaB signaling pathway

[0051] 2.5 Analyze lung Yanshu-disease targets through David database, and fit the obtained KEGG signaling pathways, such as Figure 6 As shown, it was found that Feiyanshu affects signal transduction, cell growth and death in the process of lung metastatic disease, and exerts an effect on the immune system.

[0052] 2.6 GO analysis of lung Yanshu-disease targets was performed using the Metascape database, such as Figure 7 As shown, it was found that in biological processes, Lung Yanshu mainly affects cell migration, phosphorylation regulation, and transmembrane receptor protein tyrosine kinase signal transduction; cellular components mainly affect cell membrane, local adhesion, and receptor complex; molecular functions mainly affect protein kinase activity, protein tyrosine kinase activity, phosphatase binding, etc.

[0053] 2.7 Analysis of drug targets and diseases of Feiyanshu, such as Figure 8 shown.

[0054] 3. In vivo and in vitro experiments on the treatment of lung cancer occurrence and metastasis with Feiyanshu.

[0055] 3.1 Materials and Methods

[0056] (1) Experimental animals

[0057] This experiment used C57BL / 6J male mice, 5-6 weeks old, weighing about 20±5g, provided by Jiangsu Jicui Biotechnology Co., Ltd. The experimental animals were raised in the Specific Pathogen Free (SPF) Experimental Animal Center of the Affiliated Municipal Hospital of Traditional Chinese Medicine of Shanghai University of Traditional Chinese Medicine (certificate number: SYXK (Shanghai) 2020-0014). The experimental animal breeding conditions were constant temperature and humidity (temperature about 24°C, humidity about 60%), and the light alternated day and night every 12 hours; food and drinking water were adequately supplied, and the bedding was changed once every 3 days. The mice were adapted to the SPF environment for 1 week. This experiment was approved by the Experimental Animal Welfare and Ethics Committee of the Affiliated Municipal Hospital of Traditional Chinese Medicine of Shanghai University of Traditional Chinese Medicine (ethics number: 2023012). The animal experimental operation complies with the national and the animal research management regulations of the experimental animal center of this hospital.

[0058] (2) Experimental cells

[0059] The CTC-TJH-01 cell line was created by our research group and has been deposited in the Wuhan Cell Bank; Lewis lung cancer cells (2LL cell line) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai).

[0060] (3) Drug preparation

[0061] The lyophilized powder of Feiyanshu prepared in Example 1 was stored in a refrigerator at 4° C. for later use;

[0062] (4) Reagents, consumables, and instruments

[0063] A. Main reagents: Hematoxylin-eosin stain (Zhuhai Beso Biotechnology Co., Ltd., C200401), BCA quantitative kit (Shanghai Yazyme Biotechnology Co., Ltd., ZJ101); antibody C9 (Affbiotech, DF3964), antibody CFHR5 (GeneTex, GTX109982), MBL2 (Affbiotech, DF4152), β-actin (Hangzhou Huaan Biotechnology Co., Ltd., ET1702), DAB color development kit (Beijing Solebao Technology Co., Ltd., DA1010), formic acid (Thermo Fisher Scientific, USA); Fisher Scientific, A117); SDS-PAGE protein loading buffer (Shanghai Yazyme Biotechnology Co., Ltd., PS105); RIPA lysis buffer (Biyuntian Biotechnology Co., Ltd., P0013c), dithiothreitol (Sigma, USA, 43819-5G); BSA (Sangon Biotechnology Co., Ltd., A0332); Trypsin (Promega, USA, V5117), DAPI (Affinity Biosciences, C0020), CCK8 kit (Dojin Chemical, Japan, CK04), ECL chemiluminescence kit (Shanghai Shenger Biotechnology Co., Ltd., SB-WB012), exosome tracing kit (Huaying Biotechnology, ESQ-G-001).

[0064] B. Main consumables: cell counting chamber (IBI, Germany, 80816), trypsin (Shanghai McLean Biochemical Technology Co., Ltd., T6325), fetal bovine serum (BI, Israel, 1809249), DMEM culture medium (CORNING, USA, 10-013-CVRC), penicillin-streptomycin (Hyclone, USA, SV30010), DMSO (Shanghai McLean Biochemical Technology Co., Ltd., D806647), PBS buffer (Hyclone, USA, SH30256.01), 15 / 50ml centrifuge tube (CORNING, USA, 430790, 430829), 1.5ml centrifuge tube (AXYGEN, USA, MCT-150-C), cryotube (BD, USA, 430659), culture dish / pipette / pipette gun (Eppendorf, Germany), invasion kit / Transwell chamber (CORNING, USA).

[0065] C. Main instruments: Roche cell counter analyzer (Roche, Switzerland, Cedex XS), constant temperature cell culture incubator (SANYO, Japan, MCO-18AIC), paraffin slicer (Leica, Germany, RM2125RTS), chemiluminescence imager (Tanon 5200, Shanghai Tianneng Technology Co., Ltd.), full-function microplate reader (Biotek, USA, Synergy H4), electrophoresis / transfer system (Bio-Rad), inverted fluorescence microscope (Leica, Germany, DMI3000B); high-speed refrigerated centrifuge (Eppendorf, Germany, 5804R / 5418R); ultrasonic disruptor (Ningbo Xinzhi Biotechnology Co., Ltd., JY96-IIN); MP Fastprep-24 homogenizer (MP, USA, MP Fastprep-24 5G); electronic balance (OHAUS Shanghai Ohaus International Trading Co., Ltd., AX324Z), fully automatic pathology slide scanner (Ningbo Jiangfeng Bioinformatics Technology Co., Ltd., KF-PRO-120).

[0066] (5) Animal experiments

[0067] A. Establishment of subcutaneous transplanted tumor model in mice: The modeling method was based on the previous literature of the research group. When the 2LL cell line was cultured to the logarithmic phase, 1×10 7 / ml, suspended in serum-free culture medium. 0.1ml of the cell suspension was injected into the right armpit of mice using an insulin injection needle to establish a mouse subcutaneous transplanted tumor lung metastasis model.

[0068] B. Model grouping and intervention method: On the 7th day after modeling, the mice were randomly divided into the Feijifang group and the saline control group, with 8 mice in each group; the drug concentration for experimental animals was calculated to be 2g / ml according to the human-animal drug conversion coefficient, and the lyophilized powder was dissolved into a 2g / ml decoction, 0.2ml was administered each time, and the intervention lasted for 21 days. After the treatment, the mice were anesthetized with 2% sodium pentobarbital, the chest cavity was fully exposed after anesthesia, the lungs were removed, the lung metastasis and the number of metastatic lesions were observed under a microscope, and some tissues were cut and placed in 4% paraformaldehyde for fixation for later use.

[0069] 3.2 Experimental index detection method

[0070] A. CCK8 assay to detect the cytotoxicity of Feiyanshu to CTC-TJH-01 / H1299 cell lines: CTC-TJH-01 and H1299 cells in the logarithmic growth phase were collected, washed once with PBS, and the cell concentration was adjusted to 3×10 4 / ml, then add 100μl of cell suspension (3000 cells / well) to the 96-well plate, place it in the incubator and culture it for 24h, then add the drug concentrations of 0, 50, 100, 200, 400, 800μg / ml to the corresponding wells, after the drug acts for 48h, add 20μl of CCK-8 solution to each well, continue to culture for 2h, and finally use an enzyme marker to detect the absorbance at a wavelength of 450nm to calculate the cell survival rate. [Cell survival rate = (experimental group OD-blank group OD) / (control group OD-blank group OD)×100%].

[0071] B. Transwell detection of the effect of Feiyanshu on the invasion and migration of CTC-TJH-01 / H1299 cells: Take out the invasion chamber kit from the -20℃ refrigerator, put it into a 24-well plate and place it at room temperature. After it returns to room temperature, add 500μl of serum-free DMEM medium to the upper and lower chambers of the chamber, respectively, and place it in a 37℃ incubator for 2h to rehydrate the Matrigel matrix layer. CTC-TJH-01 / H1299 cells were cultured and digested, and the cells were resuspended in serum-free medium and counted, and the cell concentration was adjusted to 1.6×10 5 100 μl / ml, add them to the upper and lower chambers respectively, then add 750 μl of drug-containing culture medium containing 20% ​​FBS to the lower chamber, and 500 μl of drug-containing cell suspension to the upper chamber. Then continue to culture in the incubator for 16 hours, then remove and discard the culture medium, stain with Giemsa stain for 5 minutes, then gently wash the Giemsa stain on the chamber with clean water, and then dry the chamber in the air at room temperature. Randomly shoot 5 fields of view under a microscope, count and statistically analyze.

[0072] C. Cell cloning experiment to detect the effect of Feiji prescription on the migration of CTC-TJH-01 / H1299 cells: The cells were seeded in 6-well plates (1×10 6 / well), and cultured in a 37°C, 5% CO2 cell culture incubator; when the cells formed a confluent monolayer, the culture medium was removed and a "scratch" was gently made with a 200 μl pipette tip; then the cells were gently rinsed twice with cold PBS, and drugs were added according to different drug concentrations. After adding the culture medium, the cells were placed in an incubator, and the cell migration was observed using an inverted microscope after 24 hours.

[0073] D. Western blot assay to detect the effect of Fei Ji Fang on the expression of exosomal proteins CFHR5 / C9 / MBL2 in CTC-TJH-01 / H1299 cells: Western blot (WB) was used to detect the expression level of exosomal proteins CFHR5 / C9 / MBL2 in the culture supernatant of CTC-TJH-01 / H1299 cells treated with Fei Yan Shu. CTC-TJH-01 / H1299 cells treated with different gradients of Fei Ji Fang were added to RIPA lysis buffer, lysed on ice for 30 min, centrifuged at 4 ° C (12000 rpm, 20 min) and the supernatant was collected. The total protein concentration of lung tissue was determined by BCA method, and 40 μL of protein was taken from each well to prepare the sample volume; according to the operating instructions of the kit, 10% separation gel and 5% concentrated gel were prepared for protein separation (concentrated gel voltage 80 V, 30 min; separation gel voltage 120 V, 45 min). The filter paper-PVDF membrane-gel-filter paper was fixed from bottom to top, and the target protein was separated by electrophoresis. The separated protein was transferred to the PVDF membrane by electricity (360mA current for 90min). After placing the PVDF in anhydrous methanol for a few seconds, 5% BSA was added for blocking for 1h. After blocking, the primary antibodies CFHR5 (1:1000), C9 (1:1000), and MBL2 (1:1000) were added, and incubated overnight at 4°C on a shaker; the membrane was washed with PBST, and the secondary antibody IgG (1:1000) was added and incubated at room temperature on a shaker for 90min. The color mixture was prepared according to the ECL chemiluminescence kit, and the PVDF membrane was immersed in it for a few seconds, and then it was placed in the gel imaging system for development and band image acquisition. The target protein and internal reference bands were analyzed using Image J software, and the band gray value was calculated.

[0074] E. Exosome tracing experiment: Extract, purify and perform tracing experiments on exosomes according to the instructions of the exosome tracing kit.

[0075] F. Immunohistochemistry (IHC) assay to detect the effect of Feiyanshu on the expression of exosomal proteins CFHR5 / C9 / MBL2 in lung tissue of tumor-bearing mice: The fixed lung tissue was embedded in paraffin and sectioned in citric acid antigen retrieval solution for antigen retrieval. After washing, the sections were incubated in 3% H 2 O 2 Incubate at room temperature for 25 minutes, then block in 3% BSA for 1 hour; add CFHR5 (1:500), MBL2 (1:500), and C9 (1:500) antibodies and incubate at 4°C overnight; wash again and add HRP-labeled secondary antibody IgG and incubate for 1 hour; then develop color according to the DAB kit operating instructions, wash and cover with hematoxylin; wash again and penetrate into 1% hydrochloric acid alcohol for differentiation, then return to the basket with ammonia water, wash with running water, dehydrate with ethanol and block; scan with a digital pathology slide scanner, use Image-Pro Plus 6.0 to count the optical density value of the number of positive cells, and calculate the average optical density value for statistical analysis.

[0076] G. Statistical methods: GraphPad Prism 8.0 software was used for statistical analysis of data, and t-test was used for pairwise comparisons. When the data followed a normal distribution, one-way analysis of variance was used to compare the differences between groups; when the data did not follow a normal distribution, the rank sum test was used. When the variances were equal, the least significant difference method was used for pairwise comparisons; when the variances were unequal, the Games-Howell method was used for pairwise comparisons. The test standard was α = 0.05, and p ≤ 0.05 indicated that the difference was statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).

[0077] 3.3 Experimental results:

[0078] (1) The inhibitory effect of Feiyanshu on metastasis in mice with subcutaneous tumor transplantation and lung metastasis model.

[0079] The status of lung metastasis is an important indicator for judging the clinical prevention and treatment of metastasis. The number of lung metastasis in the treatment group and the control group was observed under a microscope. Compared with the control group, the number of lung metastasis in the treatment group was significantly reduced (p<0.05). Compared with the control group, the body weight and tumor volume of the treatment group did not change significantly on the 21st day (p>0.05). For specific results, see Fig. 9 .

[0080] (2) Effect of Feiyanshu on the expression of exosomal proteins CFHR5 / MBL2 / C9 in lung tissue.

[0081] IHC was used to detect the expression of CFHR5 / MBL2 / C9 in lung tissue to clarify the regulatory effect of Feiyanshu on exosome proteins; compared with the control group, the treatment group could significantly reduce the expression of CFHR5 / MBL2 / C9 protein in lung tissue (p<0.05). Fig.10 .

[0082] (3) Effect of Feiyanshu on the proliferation of lung cancer cell lines CTC-TJH-01 and H1299.

[0083] In the above study, we confirmed that tumor cells can secrete exosomes, and exosomes can serve as important messengers for intercellular communication. In order to further verify the effect of Feiyanshu on the intervention of lung cancer metastasis, we used CCK8 and cell cloning experiments to reveal the effect of Feiyanshu on lung cancer cell proliferation. The CCK8 results showed that Feiyanshu had no obvious cytotoxic effect on CTC-TJH-01 at different concentrations; while it showed obvious cytotoxic effect on H1299 cells at high concentrations ( Fig.11 ).

[0084] The above experiments confirmed that Feiyanshu can inhibit the proliferation of tumor cells without obvious cytotoxic effects; it also suggested that it is safe below 400ug / ml, so the next step of the experiment will use a concentration below 400ug / ml.

[0085] (4) Study on the effect of Feiyanshu on the invasion and migration of CTC-TJH-01 and H1299 cells.

[0086] Clinical studies have found that Fei Yanshu has the effect of inhibiting lung cancer metastasis, but the specific mechanism needs to be further studied. In the above study, we found that Fei Yanshu had no inhibitory effect on the proliferation of CTC-TJH-01 and H1299 cells. To this end, we further carried out scratch and Transwell experiments to evaluate whether Fei Yanshu has an inhibitory effect on the metastasis of lung cancer cells. The results of the scratch experiment showed that at a drug concentration of 50μg / ml, Fei Yanshu could inhibit the migration of CTC-TJH-01 and H1299 cells (p<0.05), and as the drug concentration increased, its inhibitory effect gradually increased (p<0.01). The results of the Transwell experiment also showed that Fei Yanshu had a significant inhibitory effect on the migration and invasion of CTC-TJH-01 and H1299 cells (p<0.05) ( Fig.12 ).

[0087] The above research results suggest that Feiyanshu has an inhibitory effect on the metastasis of CTC-TJH-01 and H1299 cells in vitro.

[0088] (5) Exosome tracing experiments revealed the phagocytosis of CTC-TJH-01 and H1299 exosomes.

[0089] Exosomes are microvesicles wrapped by a lipid bilayer. Using PKH26 (red fluorescence) lipophilic dye labeling can clearly show the traces of exosomes. To this end, we conducted an exosome tracing experiment to observe whether the exosomes secreted by tumor cells can be engulfed by other tumor cells. The results of immunofluorescence staining showed that the exosomes secreted by CTC-TJH-01 cells can be engulfed by H1299 cells, and similarly, the exosomes secreted by H1299 cells can be engulfed by CTC-TJH-01 cells. The engulfed exosomes are mainly distributed in the cytoplasm ( Fig.13 ).

[0090] The above results suggest that exosomes can be phagocytosed by tumor cells when co-cultured with tumor cells, and also suggest that exosomes are "messengers" for information exchange between tumor cells and immune cells or distal target organs.

[0091] (6) Effect of Feiyanshu on exosomal proteins in the supernatant of CTC-TJH-01 and H1299 cell culture.

[0092] In the previous study, we studied the differentially expressed proteins in the exosomes of metastatic and non-metastatic NSCLC and found that Feiyanshu could inhibit the expression of exosome proteins identified in lung tissue. Therefore, we further detected the expression of exosome proteins in lung cancer cell lines by western blotting. The results showed that Feiyanshu had no significant regulatory effect on exosomal protein C9; while when the concentration of Feiyanshu was 50ug / ml, it had a down-regulating effect on CFHR5 and MBL2 proteins in CTC-TJH-01 and H1299 cells (p<0.05), and as the concentration of Feiyanshu increased, its inhibitory effect became more significant (p<0.01)( Fig.14 ).

[0093] The above research results suggest that Feiyanshu has the effect of inhibiting the secretion of exosome proteins by CTC-TJH-01 and H1299 cells.

Claims

1. A Chinese medicine composition for treating lung cancer, It is characterized in that The drug is prepared from the following raw materials by weight: 15-30 parts of raw astragalus, 10-15 parts of northern adenophora, 10-15 parts of asparagus, 10-15 parts of ophiopogon, 10-15 parts of poria, 15-30 parts of cyperus rotundus, 15-30 parts of lithospermum officinale, 15-30 parts of olivine, 15-30 parts of parsnip, 15-30 parts of trillium, 15-30 parts of selfheal, 15-30 parts of houttuynia cordata, and 10-15 parts of glossy privet fruit.

2. The Chinese medicine composition for treating lung cancer according to claim 1, It is characterized in that The weight proportions of the raw medicines are: 30 parts of raw astragalus, 15 parts of northern adenophora, 15 parts of asparagus, 15 parts of ophiopogon, 15 parts of tuckahoe, 15 parts of cyperus rotundus, 15 parts of lithospermum officinale, 15 parts of lithospermum officinale, 30 parts of parsnip, 15 parts of trifoliate orange, 15 parts of selfheal, 15 parts of houttuynia cordata, and 15 parts of glossy privet fruit.

3. Use of the Chinese medicine composition according to claim 1 or 2 in the preparation of a medicine for treating lung cancer.

4. Use of the Chinese medicine composition according to claim 1 or 2 in the preparation of a medicament for preventing and treating lung cancer metastasis.

5. According to the purpose of 3 or 4, It is characterized in that The Chinese medicine composition can inhibit the proliferation of lung cancer cells and promote their apoptosis. At the same time, it can exert an anti-lung cancer invasion and metastasis effect by intervening in exosomes, improve the clinical symptoms of tumor patients, regulate functional immune function, and improve the quality of life.

Citation Information

Patent Citations

  • Traditional Chinese medicinal compound preparation for preventing and treating postoperative recurrence and metastasis of lung cancer and preparation method of traditional Chinese medicinal compound preparation

    CN106511742A

  • Traditional Chinese medicine composition for preventing and treating lung cancer and application thereof

    CN107432906A

  • Medicine for treating lung cancer and preparing method thereof

    CN1507882A

  • Chinese medicine compound preparation for treating lung cancer

    CN1616077A

  • Chinese medicinal preparation for treating lung cancer and production thereof

    CN1819836A